256 related articles for article (PubMed ID: 33608696)
1. Cytomorphologic Spectrum of SMARCB1-Deficient Soft Tissue Neoplasms.
Schaefer IM; Al-Ibraheemi A; Qian X
Am J Clin Pathol; 2021 Jul; 156(2):229-245. PubMed ID: 33608696
[TBL] [Abstract][Full Text] [Related]
2. SMARCB1-deficient Tumors of Childhood: A Practical Guide.
Pawel BR
Pediatr Dev Pathol; 2018; 21(1):6-28. PubMed ID: 29280680
[TBL] [Abstract][Full Text] [Related]
3. Absence of expression of SMARCB1/INI1 in malignant rhabdoid tumors of the central nervous system, kidneys and soft tissue: an immunohistochemical study with implications for diagnosis.
Sigauke E; Rakheja D; Maddox DL; Hladik CL; White CL; Timmons CF; Raisanen J
Mod Pathol; 2006 May; 19(5):717-25. PubMed ID: 16528370
[TBL] [Abstract][Full Text] [Related]
4. SWI/SNF complex-deficient soft tissue neoplasms: An update.
Schaefer IM; Hornick JL
Semin Diagn Pathol; 2021 May; 38(3):222-231. PubMed ID: 32646614
[TBL] [Abstract][Full Text] [Related]
5. The genetic landscape of SMARCB1 alterations in SMARCB1-deficient spectrum of mesenchymal neoplasms.
Dermawan JK; Singer S; Tap WD; Nacev BA; Chi P; Wexler LH; Ortiz MV; Gounder M; Antonescu CR
Mod Pathol; 2022 Dec; 35(12):1900-1909. PubMed ID: 36088476
[TBL] [Abstract][Full Text] [Related]
6. Claudin-4 expression distinguishes SWI/SNF complex-deficient undifferentiated carcinomas from sarcomas.
Schaefer IM; Agaimy A; Fletcher CD; Hornick JL
Mod Pathol; 2017 Apr; 30(4):539-548. PubMed ID: 28084340
[TBL] [Abstract][Full Text] [Related]
7. Spectrum of cytopathologic features of epithelioid sarcoma in a series of 7 uncommon cases with immunohistochemical results, including loss of INI1/SMARCB1 in two test cases.
Rekhi B; Singh N
Diagn Cytopathol; 2016 Jul; 44(7):636-42. PubMed ID: 27145123
[TBL] [Abstract][Full Text] [Related]
8. Malignant rhabdoid tumors of the vulva versus epithelioid sarcomas: a clinicopathologic, immunohistochemical, and molecular genetics study.
Espinosa I; D'Angelo E; De Brot L; Prat J
Hum Pathol; 2023 May; 135():1-10. PubMed ID: 36863690
[TBL] [Abstract][Full Text] [Related]
9. SMARCB1/INI1-deficient epithelioid and myxoid neoplasms in paratesticular region: Expanding the clinicopathologic and molecular spectrum.
Yin X; Yang X; Wang S; Zhou J; Zhao M
Ann Diagn Pathol; 2024 Feb; 68():152242. PubMed ID: 38039617
[TBL] [Abstract][Full Text] [Related]
10. Myxoepithelioid tumour with chordoid features: a clinicopathological, immunohistochemical and genetic study of 14 cases of SMARCB1/INI1-deficient soft-tissue neoplasm.
Kinoshita I; Kohashi K; Yamamoto H; Yamada Y; Inoue T; Higaki K; Teramoto N; Oshiro Y; Nakashima Y; Oda Y
Histopathology; 2021 Oct; 79(4):629-641. PubMed ID: 33932047
[TBL] [Abstract][Full Text] [Related]
11. ERG and SALL4 expressions in SMARCB1/INI1-deficient tumors: a useful tool for distinguishing epithelioid sarcoma from malignant rhabdoid tumor.
Kohashi K; Yamada Y; Hotokebuchi Y; Yamamoto H; Taguchi T; Iwamoto Y; Oda Y
Hum Pathol; 2015 Feb; 46(2):225-30. PubMed ID: 25479928
[TBL] [Abstract][Full Text] [Related]
12. Infrequent SMARCB1/INI1 gene alteration in epithelioid sarcoma: a useful tool in distinguishing epithelioid sarcoma from malignant rhabdoid tumor.
Kohashi K; Izumi T; Oda Y; Yamamoto H; Tamiya S; Taguchi T; Iwamoto Y; Hasegawa T; Tsuneyoshi M
Hum Pathol; 2009 Mar; 40(3):349-55. PubMed ID: 18973917
[TBL] [Abstract][Full Text] [Related]
13. Differential microRNA expression profiles between malignant rhabdoid tumor and epithelioid sarcoma: miR193a-5p is suggested to downregulate SMARCB1 mRNA expression.
Kohashi K; Yamamoto H; Kumagai R; Yamada Y; Hotokebuchi Y; Taguchi T; Iwamoto Y; Oda Y
Mod Pathol; 2014 Jun; 27(6):832-9. PubMed ID: 24287458
[TBL] [Abstract][Full Text] [Related]
14. Loss of INI1 expression is characteristic of both conventional and proximal-type epithelioid sarcoma.
Hornick JL; Dal Cin P; Fletcher CD
Am J Surg Pathol; 2009 Apr; 33(4):542-50. PubMed ID: 19033866
[TBL] [Abstract][Full Text] [Related]
15. Genomic and Immunologic Characterization of INI1-Deficient Pediatric Cancers.
Forrest SJ; Al-Ibraheemi A; Doan D; Ward A; Clinton CM; Putra J; Pinches RS; Kadoch C; Chi SN; DuBois SG; Leavey PJ; LeBoeuf NR; Mullen E; Collins N; Church AJ; Janeway KA
Clin Cancer Res; 2020 Jun; 26(12):2882-2890. PubMed ID: 32122923
[TBL] [Abstract][Full Text] [Related]
16. A case of retroperitoneal tumor displaying epithelial differentiation, prominent myxoid stroma and loss of INI1/SMARCB1.
Rekhi B; Thomas A
Pathologica; 2021 Dec; 113(6):456-462. PubMed ID: 34974552
[TBL] [Abstract][Full Text] [Related]
17. Epithelioid sarcoma is associated with a high percentage of SMARCB1 deletions.
Sullivan LM; Folpe AL; Pawel BR; Judkins AR; Biegel JA
Mod Pathol; 2013 Mar; 26(3):385-92. PubMed ID: 23060122
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic regulation of SMARCB1 By miR-206, -381 and -671-5p is evident in a variety of SMARCB1 immunonegative soft tissue sarcomas, while miR-765 appears specific for epithelioid sarcoma. A miRNA study of 223 soft tissue sarcomas.
Sápi Z; Papp G; Szendrői M; Pápai Z; Plótár V; Krausz T; Fletcher CD
Genes Chromosomes Cancer; 2016 Oct; 55(10):786-802. PubMed ID: 27223121
[TBL] [Abstract][Full Text] [Related]
19. Poorly differentiated chordoma showing loss of SMARCB1/INI1: Clinicopathological and radiological spectrum of nine cases, including uncommon features of a relatively under-recognized entity.
Rekhi B; Michal M; Ergen FB; Roy P; Puls F; Haugland HK; Soylemezoglu F; Kosemehmetoglu K
Ann Diagn Pathol; 2021 Dec; 55():151809. PubMed ID: 34482218
[TBL] [Abstract][Full Text] [Related]
20. Oncogenic roles of SMARCB1/INI1 and its deficient tumors.
Kohashi K; Oda Y
Cancer Sci; 2017 Apr; 108(4):547-552. PubMed ID: 28109176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
